insights_auto
Why is DMYD-B up 2,37%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
1,04 SEK
arrow_upward
+2,37%(+0,024) 1D
13 қаз., 14:15:20 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
1,03 SEK
High
1,08 SEK
Low
1,01 SEK
Mkt. cap
157,24 млн
Avg. vol.
796,34 м.
Volume
611,39 м.
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 млн
No. of employees
42
Open
1,03 SEK
High
1,08 SEK
Low
1,01 SEK
Mkt. cap
157,24 млн
Avg. vol.
796,34 м.
Volume
611,39 м.
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 млн
No. of employees
42
News stories
From web sources and news partners
FinancialContent
·
15 минут бұрын
Albertsons (NYSE:ACI) Reports Q3 CY2026 In Line With Expectations
The Avery Journal-Times
·
43 минут бұрын
XCF Global (Nasdaq:SAFX) Announces $12M+ in Gross Product Sales and Shipments of 1.4 Million Gallons of Renewable Diesel in September
MarketBeat
·
6 минут бұрын
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC Wainwright
24/7 Wall St.
·
1 сағат бұрын
Buffett Says a Know-Nothing Investor Can Beat the Pros. $250 a Month in the S&P 500 Could Turn Into $508,000
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB